NCT04783207 (ENDURO) is a NA clinical trial of Mitopure in Healthy, sponsored by Amazentis SA.

Who is sponsoring NCT04783207?

NCT04783207 is sponsored by Amazentis SA.

What drugs are being tested in NCT04783207?

Interventions in NCT04783207: Mitopure, Placebo.

Is NCT04783207 still recruiting?

NCT04783207 is currently completed. Last updated 31 August 2023.

Last reviewed 2023-08-31 · How we verify

NCT04783207: ENDURO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Mitopure (Urolithin A) on Skeletal Muscle Function, Iron Metabolism and Endurance Performance

Completed NA Last updated 31 August 2023

What this trial tests

NA trial testing Mitopure in Healthy in 42 participants. Completed in 30 August 2023.

Timeline

21 April 2021

Primary endpoint
30 May 2022

30 August 2023

Quick facts

Lead sponsor	Amazentis SA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	42
Start date	21 April 2021
Primary completion	30 May 2022
Estimated completion	30 August 2023
Sites	1 location across Australia

Drugs / interventions tested

Mitopure
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Amazentis SA — full company profile →

Who can join

Adults 18 to 40, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled study enrolling 36 (16 Elite and 20 Sub-Elite trained endurance runners (18 placebo and 18 Mitopure intervention) who are 18-40 years of age. Mitopure or Placebo supplement, will be given as a daily oral dose for 4-weeks.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Potential of Small Molecules to Modulate the Mitochondria-Endoplasmic Reticulum Interplay in Alzheimer's Disease.
Dentoni G, Castro-Aldrete L, Naia L, Ankarcrona M. · · 2022 · cited 20× · PMID 36092728 · DOI 10.3389/fcell.2022.920228
Mitophagy Activation by Urolithin A to Target Muscle Aging.
Faitg J, D'Amico D, Rinsch C, Singh A. · · 2024 · cited 11× · PMID 37925671 · DOI 10.1007/s00223-023-01145-5
Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners.
Whitfield J, McKay AKA, Tee N, McCormick R, et al · · 2025 · cited 2× · PMID 40839339 · DOI 10.1007/s40279-025-02292-5
Mitophagy in the pathogenesis and management of disease.
Wang Q, Sun Y, Li TY, Auwerx J. · · 2026 · cited 1× · PMID 41486294 · DOI 10.1038/s41422-025-01203-7
Insights into the therapeutic strategies for aging and aging-associated diseases.
Dong R, Wu Q, Kan J, Fu C, et al · · 2026 · PMID 42225652 · DOI 10.1038/s41392-026-02662-z

Verify or expand the search:

Other trials of Mitopure

Trials testing the same drug.

NCT07517913 — Cerebrospinal Fluid Kinetics of Urolithin A · NA · not yet recruiting
NCT04985630 — The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots · NA · recruiting
NCT03283462 — Bioenergetics and Muscle Function Improvement With AMAZ-02 in Elderly Skeletal Muscle (ENERGIZE Trial) · NA · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Amazentis SA trials

Trials by the same sponsor.

NCT07517913 — Cerebrospinal Fluid Kinetics of Urolithin A · NA · not yet recruiting
NCT07517874 — Human Skin Safety Testing of 1 Mitopure Topical Products Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volun · NA · not yet recruiting
NCT07517887 — Anti-aging Efficacy Study on One Cosmetic Product Containing Mitopure · NA · not yet recruiting
NCT07517900 — Human Skin Safety Testing of 1 Mitopure Topical Product Using a Clinical Safety in Use Study in Healthy Volunteers · NA · not yet recruiting
NCT07231783 — The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04783207 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amazentis SA
Last refreshed: 31 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04783207.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing